Drug Profile
OMS 210
Alternative Names: OMS210Latest Information Update: 26 Sep 2014
Price :
$50
*
At a glance
- Originator Unknown
- Developer Lotus Pharmaceuticals
- Class Retinoids
- Mechanism of Action Serotonin 3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Irritable bowel syndrome
Most Recent Events
- 01 Mar 2014 No development reported - Phase-II for Irritable bowel syndrome in Belgium, Czech Republic, Germany, Hungary and the United Kingdom (PO)
- 23 Feb 2012 Lotus Pharmaceuticals completes a phase IIa trial in Irritable bowel syndrome in Belgium, Czech Republic, Germany, Hungary and the United Kingdom (EudraCT2010-019343-20)